MNG763
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.438
- INTERFERON_ALPHA_RESPONSE+0.337
- KRAS_SIGNALING_DN+0.329
- ALLOGRAFT_REJECTION+0.242
- INTERFERON_GAMMA_RESPONSE+0.208
- BILE_ACID_METABOLISM+0.152
- COAGULATION+0.047
- APICAL_JUNCTION+0.042
- UV_RESPONSE_UP+0.034
- INFLAMMATORY_RESPONSE+0.029
Top 10 suppressed
- E2F_TARGETS-0.565
- G2M_CHECKPOINT-0.547
- MITOTIC_SPINDLE-0.523
- PROTEIN_SECRETION-0.471
- TGF_BETA_SIGNALING-0.418
- CHOLESTEROL_HOMEOSTASIS-0.390
- MTORC1_SIGNALING-0.372
- ANDROGEN_RESPONSE-0.355
- UNFOLDED_PROTEIN_RESPONSE-0.351
- MYC_TARGETS_V1-0.333
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13311156 | — | — | 0.893 |
| 2 | TCGA-49-AAR2-01A-11R-A39D-07 | — | cohortA3 | 0.885 |
| 3 | TCGA-49-AAQV-01A-11R-A39D-07 | — | cohortA1 | 0.883 |
| 4 | SRR8392892 | — | cohortA1 | 0.882 |
| 5 | MNG882 | — | — | 0.881 |
| 6 | MDT-AP-1204 | Med | Medulloblastoma | 0.873 |
| 7 | aad89bba-d9dc-4a93-8e77-26f2c1ba1c3f | — | — | 0.868 |
| 8 | SRR8942994 | — | — | 0.866 |
| 9 | MDT-AP-2296 | Med | Medulloblastoma | 0.864 |
| 10 | SRR1473654 | GTEX | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.438 | Cobimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.337 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.329 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.242 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.208 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.152 | Inavolisib | — uncovered |
| COAGULATION | 0.047 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.042 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.034 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.029 | Idelalisib | — uncovered |
| MYOGENESIS | 0.016 | Inavolisib | — uncovered |